ARTICLE | Clinical News
TheraCIM h-R3 nimotuzumab: Phase I/II start
August 22, 2005 7:00 AM UTC
YM will begin a Canadian and Korean Phase I/II trial in about 100 stage IIb and III NSCLC patients to compare TheraCIM plus radiation vs. radiation alone. ...